Sobi™ to acquire Synagis® US rights from AstraZeneca
- Creates a platform for global growth

Investor Presentation l 13 November 2018

Forward looking statements

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements, including statements regarding the potential benefits that may be derived from the acquisition of Synagis and the rights to MEDI8897, plans and expected timing with respect to the potential approval of MEDI8897 in the US, as well as potential future sales of Synagis and MEDI8897. These forward-looking statements are based on management expectations and assumptions as of the date of this presentation, and actual results may differ materially from those in these forward-looking statements as a result of various factors. Forward-looking statements speak only as of the date of this presentation and Sobi does not undertake any obligation to update or revise these statements, except as may be required by law or regulation.

AGENDA

Introduction

Transaction overview

Disease and product overview

Strategic rationale

Summary

PRESENTERS

Guido Oelkers
Chief Executive Officer and President

Henrik Stenqvist
Chief Financial Officer

Milan Zdravkovic
Head of Research & Development and
Chief Medical Officer

AGENDA

Introduction

Transaction overview

Disease and product overview

Strategic rationale

Summary

Sobi’s vision is to become global leaders in rare diseases

Further internationalisation
and commercialisation of Haemophilia

Build Specialty Care
as the preferred partner

Strengthen position
in the US and EMENAR

Build pipeline
and self-sustained R&D

Vision

To be recognised as a global leader in providing innovative treatments that transform lives for individuals with rare diseases

Strong growth over the past years

Main growth drivers

- Extremely successful Haemophilia launch
- Kineret strong double-digit growth

Growth opportunities

- Further growth opportunities in Haemophilia and penetration and internationalisation
- Increase US market presence and footprint
- Broaden Specialty Care portfolio in areas of expertise

Sobi revenue[1]
SEK M



1. Sobi Annual Reports 2013–2017
2. Revised outlook published on 31 October 2018
3. Estimated

Components of the transaction

SYNAGIS®
PALIVIZUMAB

- Perpetual rights to Synagis® (palivizumab) in the US
- Synagis, the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk infants
- Access to a proven US commercial infrastructure

MEDI8897

- Right to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US
- MEDI8897 is a follow-on candidate to Synagis and a monoclonal antibody (mAb) being investigated for the prevention of lower respiratory tract infection (LRTI) caused by RSV in a larger patient population

The main theses of the transaction

Longitudinal earnings stream

Build a business on the combination of a unique biologic with access to the 50% of earnings of a follow on compound in a much broader patient population

Synagis connects with Sobi's DNA

Synagis is a product that connects with our DNA, meaning focus on rare conditions and expertise in the paediatric field

Access to talent pool to build US platform

Double our commercial footprint in the US – allowing Sobi to expand its presence beyond Synagis

The transaction will support three areas of our strategy



AGENDA

Introduction

Transaction overview

Disease and product overview

Strategic rationale

Summary

Overview of transaction terms

Upfront

USD 1,500 M (SEK 13.6 B)

Financing of upfront consideration

- USD 1,000 M (SEK 9.1 B) in cash; Fully committed credit facilities in place
- 24.2 million newly issued Sobi shares corresponding to a value of USD 500 M (SEK 4.5 B)
- Implied AstraZeneca ownership of 8.1 per cent

Deferred & Milestones

Synagis

- Up to USD 470 M (SEK 4.3 B) in sales-related milestones for Synagis, starting from 2026 and linked to enhanced long term performance

MEDI8897

- Deferred payments of USD 20 M (SEK 181 M) per year from 2019-21
- USD 175 M (SEK 1.6 B) milestone upon BLA submission to FDA
- Potential net payments of approx. USD 110 M (SEK 1 B) on achievement of other MEDI8897 profit and development milestones, expected from 2023

The completion of the acquisition is subject to certain customary conditions and regulatory approvals
USD/SEK FX of 9.05 applied

Pro forma financial impact

	Key Financials FY2018E (SEK)		Key Financials LTM 30 June 2018 (SEK)	Combined Pro forma
Revenues	8.95 billion[1]	+	2.4 billion[2]	11.4 billion
EBITA[3] Margin	38-39%[1]		>60%	>40%

Enhances financial capacity

1. Revised outlook published on 31 October 2018. EBITA expected in the range of SEK 8.9-9.0 M.
2. Based on Synagis US LTM 30 June 2018 revenues reported by AstraZeneca, converted at a USD/SEK FX of 9.05
3. Financial measure not defined according to IFRS (alternative performance measure). EBITA is earnings before interest, tax and amortisation

AGENDA

Introduction

Transaction overview

Disease and product overview

Strategic rationale

Summary

RSV infection may be associated with significant morbidity

- Respiratory syncytial virus (RSV) is a major cause of respiratory illness in young children
- Almost all children have been infected by 4 years of age
- Symptoms may be like common cold and can develop into bronchiolitis and pneumonia
- Severe disease in children most often occurs in premature children and/or children with cardiopulmonary disease
- ~57k hospitalisations each year in under 5 year-olds with associated morbidity
- For the care of high-risk infants, prevention is critical

Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV): Trends and Surveillance;
Hall CB et al. The burden of respiratory syncytial virus infection in young children. New Engl J Med. 2009.
Merck Manual 2018.

Synagis® (palivizumab) is the only therapy approved for the prevention of serious RSV disease in high-risk infants



- Recombinant humanised monoclonal ab that provides protection against RSV
- Well established safety and efficacy profile
- Indicated for prevention of serious lower respiratory tract disease caused by RSV in infants and young children at high-risk for severe RSV disease
- Clinical studies have shown reduced risk of RSV-related hospitalisations in high-risk infants (pre-mature, and/or cardiopulmonary disease)

For further information please see USPI for Synagis®

MEDI8897 is an extended half-life anti-RSV F monoclonal antibody



- Human antibody against RSV with greater potency than palivizumab in *in vitro* and pre-clinical models
- Engineered to have an extended half-life thereby potentially enabling a single dose to cover an RSV season
- Received Fast Track Designation from the US FDA in 2015
- MEDI8897 is currently in an ongoing Phase IIb study
- The current development plan includes initiation of a Phase III trial in healthy full-term and late pre-term infants

Zhu et al., Sci. Transl. Med. 9 (2017)
Domachowske et al Pediatr Infect Dis J 2018;37:886-892
AstraZeneca Q3. November 2018. https://www.astrazeneca.com/content/dam/az/PDF/2018/Q3/Year-To-Date_and_Q3_2018_Results_announcement.pdf
MEDI8897 is being developed in partnership between AstraZeneca and Sanofi Pasteur

AGENDA

Introduction

Transaction overview

Disease and product overview

Strategic rationale

Summary

Strategic rationale

Diversify Sobi's revenue base into Immunology

Accelerate build up of Sobi's US commercialisation platform

Enhance financial capacity

Diversify revenue base in Specialty Care – Immunology

Haemophilia

ELOCTA®▼
efmoroctocog alfa
(recombinant human coagulation factor VIII, Fc fusion protein)

ALPROLIX®▼
eftrenonacog alfa
(recombinant human coagulation factor IX, Fc fusion protein)

Specialty Care

Immunology

SYNAGIS®
PALIVIZUMAB

emapalumab

Kineret®
(anakinra)

Gen/Met & Other

Orfadin®
nitisinone

RAVICTI®
(glycerol phenylbutyrate) Oral Liquid

XIAPEX®
collagenase clostridium histolyticum

Diversify Sobi's revenue base into Immunology

- Provides further diversification into immunology
- Adds important new product with an orphan-like paediatric patient population with a high unmet medical need
- Commercial platform enables future new launches

Sobi Specialty Care Portfolio[1]

Sales in SEK M



1. Based on Synagis LTM 30 June 2018 revenues of 269 MUSD reported by AstraZeneca, converted at a SEK/USD FX of 9.05 and Sobi Outlook published on 31 October 2018.

Transformative to Sobi US

Pro Forma 2018 total revenue contribution

Pre-Transaction



- Well established European sales and marketing platform

Post-Transaction[1]



- More than doubles US sales
- Accelerates build up of US commercial platform
- Enhances partnering attractiveness

The US is of critical importance to Sobi, being approx. 50% of the global Rare Disease market

1. Based on Synagis LTM 30 June 2018 revenues of 269 MUSD reported by AstraZeneca, converted at a SEK/USD FX of 9.05 and Sobi Outlook published on 31 October 2018.

AGENDA

Introduction

Transaction overview

Disease and product overview

Strategic rationale

Summary

Strategic rationale

Diversify Sobi's revenue base into Immunology

Accelerate build up of Sobi's US commercialisation platform

Enhance financial capacity

Q&A


sobi
Pioneer in Rare Diseases